The University of Chicago Header Logo
Last Name



This is a "connection" page, showing publications co-authored by Philip P. Connell and Brian Budke.

Connection Strength
  1. Budke B, Zhong A, Sullivan K, Park C, Gittin DI, Kountz TS, Connell PP. Noncanonical NF-?B factor p100/p52 regulates homologous recombination and modulates sensitivity to DNA-damaging therapy. Nucleic Acids Res. 2022 06 24; 50(11):6251-6263.
    View in: PubMed
    Score: 0.981
  2. Budke B, Tueckmantel W, Miles K, Kozikowski AP, Connell PP. Optimization of Drug Candidates That Inhibit the D-Loop Activity of RAD51. ChemMedChem. 2019 05 17; 14(10):1031-1040.
    View in: PubMed
    Score: 0.786
  3. Budke B, Lv W, Kozikowski AP, Connell PP. Recent Developments Using Small Molecules to Target RAD51: How to Best Modulate RAD51 for Anticancer Therapy? ChemMedChem. 2016 11 21; 11(22):2468-2473.
    View in: PubMed
    Score: 0.663
  4. Budke B, Chan YL, Bishop DK, Connell PP. Real-time solution measurement of RAD51- and RecA-mediated strand assimilation without background annealing. Nucleic Acids Res. 2013 Jul; 41(13):e130.
    View in: PubMed
    Score: 0.521
  5. Budke B, Kalin JH, Pawlowski M, Zelivianskaia AS, Wu M, Kozikowski AP, Connell PP. An optimized RAD51 inhibitor that disrupts homologous recombination without requiring Michael acceptor reactivity. J Med Chem. 2013 Jan 10; 56(1):254-63.
    View in: PubMed
    Score: 0.508
  6. Budke B, Logan HL, Kalin JH, Zelivianskaia AS, Cameron McGuire W, Miller LL, Stark JM, Kozikowski AP, Bishop DK, Connell PP. RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells. Nucleic Acids Res. 2012 Aug; 40(15):7347-57.
    View in: PubMed
    Score: 0.486
  7. Pointer KB, Budke B, Connell PP. Targeting Non-Canonical NF?B2 to Determine the Effects on Radiation Sensitization. Int J Radiat Oncol Biol Phys. 2021 Nov 01; 111(3S):e229-e230.
    View in: PubMed
    Score: 0.235
  8. Mason JM, Logan HL, Budke B, Wu M, Pawlowski M, Weichselbaum RR, Kozikowski AP, Bishop DK, Connell PP. The RAD51-stimulatory compound RS-1 can exploit the RAD51 overexpression that exists in cancer cells and tumors. Cancer Res. 2014 Jul 01; 74(13):3546-55.
    View in: PubMed
    Score: 0.139
  9. Pitroda SP, Pashtan IM, Logan HL, Budke B, Darga TE, Weichselbaum RR, Connell PP. DNA repair pathway gene expression score correlates with repair proficiency and tumor sensitivity to chemotherapy. Sci Transl Med. 2014 Mar 26; 6(229):229ra42.
    View in: PubMed
    Score: 0.138
  10. Chlenski A, Park C, Dobratic M, Salwen HR, Budke B, Park JH, Miller R, Applebaum MA, Wilkinson E, Nakamura Y, Connell PP, Cohn SL. Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma. Mol Cancer Ther. 2019 03; 18(3):507-516.
    View in: PubMed
    Score: 0.048
  11. Lv W, Budke B, Pawlowski M, Connell PP, Kozikowski AP. Development of Small Molecules that Specifically Inhibit the D-loop Activity of RAD51. J Med Chem. 2016 05 26; 59(10):4511-25.
    View in: PubMed
    Score: 0.040
  12. Thierry S, Benleulmi MS, Sinzelle L, Thierry E, Calmels C, Chaignepain S, Waffo-Teguo P, Merillon JM, Budke B, Pasquet JM, Litvak S, Ciuffi A, Sung P, Connell P, Hauber I, Hauber J, Andreola ML, Delelis O, Parissi V. Dual and Opposite Effects of hRAD51 Chemical Modulation on HIV-1 Integration. Chem Biol. 2015 Jun 18; 22(6):712-23.
    View in: PubMed
    Score: 0.038
  13. Mason JM, Dusad K, Wright WD, Grubb J, Budke B, Heyer WD, Connell PP, Weichselbaum RR, Bishop DK. RAD54 family translocases counter genotoxic effects of RAD51 in human tumor cells. Nucleic Acids Res. 2015 Mar 31; 43(6):3180-96.
    View in: PubMed
    Score: 0.037
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.